Unlocking the potential of gene therapy for patients with rare and orphan diseases

About Medgenics

At Medgenics, we share one singular focus - to transform the lives of our patients through the development of innovative and best-in-class therapies. We are dedicated to developing the our unique technology platform (TARGT) for the express purpose of treating patients with rare and orphan diseases.

Spotlight

TARGT has demonstrated several advantages over current gene or protein therapy, including efficacy, safety and capital efficiency.

Latest News

12-01-14 Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock 11-25-14 Medgenics to Present at 26th Annual Piper Jaffray Healthcare Conference 11-25-14 Medgenics Prices Public Offering of Common Stock